Updated: Different way to go after KRAS mutant tumors? Novo-backed biotech nabs $50M to wrap early studies

Amgen and Mirati may be duking it out over who gets to set the standard of care in KRAS mutant cancer, but a small company believes it can offer an even more powerful alternative.

That promise is drawing new investors to Inspirna, which has just bagged a $50 million Series...

Click to view original post